Insider · CIK 0001914647
Jeffrey Alan Jones
Files at CGEM (Cullinan Oncology, Inc.). First filing Dec 20, 2023, latest Feb 25, 2026.
In brief
Jeffrey Alan Jones files SEC Form 4 as officer at CGEM (Cullinan Oncology, Inc.). Since Dec 20, 2023, Jeffrey Alan Jones has reported 0 open-market buys worth $0 and 7 open-market sells worth $293k, the latest filed on Feb 25, 2026.
A track record needs three past buys with six months of prices behind them; Jeffrey Alan Jones has 0, so none is measured yet.
The newest scored trade: sold $66k of CGEM on Feb 24, 2026, filed Feb 25, 2026, scored 38 (weak). In the last 12 months: 0 buys worth $0 and 3 sells worth $179k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CGEM: Cullinan Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Cullinan Oncology, Inc. | $66k 4,582 shares | -3% | +148% from low0% from high | |
| 38Weak | Cullinan Oncology, Inc. | $68k 4,982 shares | -3% | +137% from low-2% from high | |
| 36Weak | Cullinan Oncology, Inc. | $45k 4,632 shares | -3% | +74% from low-23% from high | |
| 36Weak | Cullinan Oncology, Inc. | $42k 4,895 shares | -3% | 0% from low-53% from high | |
| 37Weak | Cullinan Oncology, Inc. | $53k 4,632 shares | -4% | - | |
| 30Weak | Cullinan Oncology, Inc. | $16k 1,860 shares | -3% | +20% from low-29% from high | |
| 30Weak | Cullinan Oncology, Inc. | $3,173 386 shares | -1% | +16% from low-32% from high |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | CGEM Cullinan Oncology, Inc. | SOpen-market sale Common Stock | -4,582 | $14.47 | $66k | 159,968 | Feb 25, 2026 |
| Feb 20, 2026 | CGEM Cullinan Oncology, Inc. | SOpen-market sale Common Stock | -4,982 | $13.62 | $68k | 164,550 | Feb 23, 2026 |
| Feb 18, 2026 | CGEM Cullinan Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Feb 19, 2026 |
| Dec 18, 2025 | CGEM Cullinan Oncology, Inc. | SOpen-market sale Common Stock | -4,632 | $9.67 | $45k | 169,532 | Dec 19, 2025 |
| Feb 25, 2025 | CGEM Cullinan Oncology, Inc. | SOpen-market sale Common Stock | -4,895 | $8.53 | $42k | 174,164 | Feb 27, 2025 |
| Feb 19, 2025 | CGEM Cullinan Oncology, Inc. | AGrant or award Common Stock | +65,000 | $0.00 | $0 | 179,059 | Feb 21, 2025 |
| Feb 19, 2025 | CGEM Cullinan Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Feb 21, 2025 |
| Dec 18, 2024 | CGEM Cullinan Oncology, Inc. | SOpen-market sale Common Stock | -4,632 | $11.41 | $53k | 114,059 | Dec 20, 2024 |
| Dec 21, 2023 | CGEM Cullinan Oncology, Inc. | SOpen-market sale Common Stock | -1,860 | $8.50 | $16k | 56,191 | Dec 22, 2023 |
| Dec 18, 2023 | CGEM Cullinan Oncology, Inc. | SOpen-market sale Common Stock | -386 | $8.22 | $3,173 | 58,051 | Dec 20, 2023 |
Questions about Jeffrey Alan Jones
Answered from the filings on this page, as of the latest one.
Is Jeffrey Alan Jones buying or selling?
In the last 12 months Jeffrey Alan Jones reported 0 open-market buys worth $0 and 3 open-market sells worth $179k on SEC Form 4; the latest was sold $66k of CGEM on Feb 24, 2026. Grants, option exercises and tax withholding are not counted.
How did Jeffrey Alan Jones's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey Alan Jones has 0.
Where does Jeffrey Alan Jones file Form 4?
Jeffrey Alan Jones has filed Form 4 at CGEM (Cullinan Oncology, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.